GLP1R and Hepatic steatosis: Recently, in phase 2 clinical trials, using glucagon-like peptide-1 receptor (GLP-1R) agonists (like liraglutide and semaglutide) in patients with NAFLD has also been shown to significantly improve inflammation, hepatic steatosis, fibrosis, and promote weight loss [104].